Connection

Jean-Charles Soria to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Lung Neoplasms.
Jean-Charles Soria
Connection Strength
3.243
Lung Neoplasms
  1. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. JAMA Oncol. 2018 09 01; 4(9):1189-1197.
    View in: PubMed
    Score: 0.219
  2. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 09; 101:201-209.
    View in: PubMed
    Score: 0.218
  3. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 01 11; 378(2):113-125.
    View in: PubMed
    Score: 0.208
  4. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. Eur J Cancer. 2017 11; 86:186-196.
    View in: PubMed
    Score: 0.206
  5. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Dec 20; 35(36):4027-4034.
    View in: PubMed
    Score: 0.206
  6. Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. Eur J Cancer. 2017 11; 85:155-157.
    View in: PubMed
    Score: 0.205
  7. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med. 2017 03 13; 15(1):55.
    View in: PubMed
    Score: 0.198
  8. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 03 04; 389(10072):917-929.
    View in: PubMed
    Score: 0.196
  9. Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2017; 37:12-17.
    View in: PubMed
    Score: 0.195
  10. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012 May 01; 18(9):2443-51.
    View in: PubMed
    Score: 0.140
  11. [Biomarkers of carcinogenesis of the upper and lower airway epithelium and the role of chemoprevention]. Bull Cancer. 2001 Apr; 88(4):351-61.
    View in: PubMed
    Score: 0.066
  12. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med. 2020 06; 8(6):542-544.
    View in: PubMed
    Score: 0.061
  13. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018 11 01; 4(11):1543-1552.
    View in: PubMed
    Score: 0.055
  14. LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer. Clin Lung Cancer. 2019 03; 20(2):66-73.e6.
    View in: PubMed
    Score: 0.055
  15. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J. 2018 10; 52(4).
    View in: PubMed
    Score: 0.055
  16. Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 10 20; 36(30):2995-3006.
    View in: PubMed
    Score: 0.055
  17. Osimertinib in EGFR Mutation-Positive Advanced NSCLC. N Engl J Med. 2018 03 29; 378(13):1262-1263.
    View in: PubMed
    Score: 0.053
  18. DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. J Clin Invest. 2018 04 02; 128(4):1671-1687.
    View in: PubMed
    Score: 0.053
  19. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018 Mar 01; 4(3):351-357.
    View in: PubMed
    Score: 0.053
  20. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018 01; 88:38-47.
    View in: PubMed
    Score: 0.052
  21. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer. 2017 10; 112:62-68.
    View in: PubMed
    Score: 0.051
  22. Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 2017 10; 112:10-15.
    View in: PubMed
    Score: 0.051
  23. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clin Lung Cancer. 2018 01; 19(1):74-83.e11.
    View in: PubMed
    Score: 0.050
  24. A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clin Cancer Res. 2017 Sep 15; 23(18):5366-5373.
    View in: PubMed
    Score: 0.050
  25. Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 2017 07; 109:101-108.
    View in: PubMed
    Score: 0.050
  26. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017 Jun 06; 116(12):1505-1512.
    View in: PubMed
    Score: 0.050
  27. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. J Clin Oncol. 2017 Jun 20; 35(18):2018-2027.
    View in: PubMed
    Score: 0.050
  28. Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2017 Jun; 79(6):1257-1265.
    View in: PubMed
    Score: 0.050
  29. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. Cancer Treat Rev. 2017 Apr; 55:83-95.
    View in: PubMed
    Score: 0.050
  30. Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient. Lung Cancer. 2017 06; 108:72-74.
    View in: PubMed
    Score: 0.049
  31. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 02; 387(10026):1415-1426.
    View in: PubMed
    Score: 0.046
  32. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. Ann Pathol. 2016 Jan; 36(1):94-102.
    View in: PubMed
    Score: 0.046
  33. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014 Jan 10; 32(2):68-75.
    View in: PubMed
    Score: 0.040
  34. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer. 2004 Mar 22; 90(6):1222-9.
    View in: PubMed
    Score: 0.020
  35. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. Eur J Cancer. 2018 11; 104:1-8.
    View in: PubMed
    Score: 0.014
  36. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018 02; 14(2):e1005965.
    View in: PubMed
    Score: 0.013
  37. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 03 20; 36(9):850-858.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.